- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.11. | Marvel Biosciences Corp: Marvel Biosciences grants 35,697 deferred share units | 1 | Stockwatch | ||
| MARVEL BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 10.11. | Marvel Biosciences Corp.: Marvel Biosciences Announces Grant of Deferred Share Units | 329 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 10, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces... ► Artikel lesen | |
| 03.10. | Marvel Biosciences Corp: Marvel Biosciences accelerates expiry of warrants | 2 | Stockwatch | ||
| 03.10. | Marvel Biosciences Corp.: Marvel Biosciences Announces Acceleration of Warrant Expiry Date | 335 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 3, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is... ► Artikel lesen | |
| 19.08. | Marvel Biosciences Corp: Marvel Biosciences receives Chinese patent for MB-204 | 1 | Stockwatch | ||
| 18.08. | Marvel Biosciences Corp.: Marvel Biosciences Granted Chinese Patent for Lead Therapeutic Candidate MB-204 | 448 | Newsfile | Calgary, Alberta--(Newsfile Corp. - August 18, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the... ► Artikel lesen | |
| 12.08. | Marvel Biosciences Corp: Marvel Biosciences grants 142,987 deferred share units | 1 | Stockwatch | ||
| 12.08. | Marvel Biosciences Corp.: Marvel Biosciences Announces Grant of Deferred Share Units | 494 | Newsfile | Calgary, Alberta--(Newsfile Corp. - August 11, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces... ► Artikel lesen | |
| 26.05. | Marvel Biosciences Corp: Marvel Biosciences 8.15-million-share private placement | 1 | Stockwatch | ||
| 13.05. | Marvel Biosciences Corp.: Marvel Biosciences Announces Closing of Private Placement | 548 | Newsfile | Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces... ► Artikel lesen | |
| 02.05. | Marvel Biosciences Corp.: Marvel Biosciences Announces Closing of Second Tranche of Private Placement | 330 | Newsfile | Calgary, Alberta--(Newsfile Corp. - May 2, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased... ► Artikel lesen | |
| 30.04. | Marvel Biosciences Corp.: Marvel Announces the Second of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide Following Cessation of Drug Treatment | 184 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 30, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or... ► Artikel lesen | |
| 16.04. | Marvel Biosciences Corp.: Marvel Biosciences to Give Oral Presentation at The Annual IRSF Rett Syndrome Scientific Meeting | 149 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 16, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (together "Marvel"), are pleased... ► Artikel lesen | |
| 14.04. | Marvel Biosciences Corp.: Marvel Biosciences Selected to Present Alzheimer's Research at the 2025 Alzheimer's Association International Conference | 162 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 14, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the... ► Artikel lesen | |
| 28.03. | Marvel Biosciences Corp.: Marvel Biosciences Announces Private Placement | 702 | Newsfile | Calgary, Alberta--(Newsfile Corp. - March 28, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased... ► Artikel lesen | |
| 17.03. | Marvel Biosciences Corp.: Marvel to File for Orphan Drug Designation with The U.S. FDA for MB-204 as a Treatment for Rett Syndrome | 298 | Newsfile | Calgary, Alberta--(Newsfile Corp. - March 17, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or... ► Artikel lesen | |
| 13.03. | Marvel Biosciences Corp.: Marvel Announces First of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide | 248 | Newsfile | Calgary, Alberta--(Newsfile Corp. - March 13, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or... ► Artikel lesen | |
| 11.03. | Marvel Biosciences Corp.: Marvel Presenting at the 2025 Bloom Burton & Co. Conference | 172 | Newsfile | Calgary, Alberta--(Newsfile Corp. - March 11, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or... ► Artikel lesen | |
| 16.01. | Marvel Biosciences Corp.: Marvel Biosciences Announces Notice of Allowance of Composition of Matter Patent for Its Lead Molecule MB-204 in China | 364 | Newsfile | Calgary, Alberta--(Newsfile Corp. - January 16, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company"... ► Artikel lesen | |
| 07.01. | Marvel Biosciences Corp.: Marvel Biosciences Announces Private Placement for up to $2.5 Million | 374 | Newsfile | Calgary, Alberta--(Newsfile Corp. - January 7, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") is pleased to announce that it intends to complete a non-brokered... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,440 | +3,60 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 169,48 | -10,72 % | Praxis Precision Medicines drops after Culper Research short call | ||
| BIONTECH | 84,55 | -3,87 % | BioNTech Aktie: Große Gewinne? - Bayer, Evotec, Hensoldt, Kontron und Rheinmetall im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,81 | -0,09 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| OLEMA PHARMACEUTICALS | 22,070 | +13,41 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| EVOTEC | 5,176 | +0,27 % | Eilmeldung am Abend: EVOTEC SE kurz vor Entscheidungsphase | ||
| RECURSION PHARMACEUTICALS | 3,845 | -4,71 % | Is Recursion Pharmaceuticals a Meme Stock? | ||
| COGENT BIOSCIENCES | 35,310 | +1,06 % | COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know | ||
| ANNEXON | 4,490 | +10,73 % | Annexon stock rises after director purchases shares | ||
| GUBRA | 63,55 | +6,27 % | Von Novo Nordisk zu Unrecht in Sippenhaft genommen: Gubra-Aktie mit Kaufsignal | Auf Jahressicht notiert die Aktie von Gubra rund ein Fünftel tiefer. Immer wieder wurde das Papier des dänischen Wirkstoffforschers mit einem Fokus auf die Entwicklung von Adipositas-Medikamenten von... ► Artikel lesen | |
| ARCELLX | 89,91 | +0,21 % | Arcellx stock initiated at Peerperform by Wolfe Research amid BCMA market competition | ||
| ARCUTIS BIOTHERAPEUTICS | 27,750 | -0,54 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| NUVATION BIO | 6,955 | -2,86 % | Nuvation Bio (NUVB) Jumps to 3-Year High on Bullish Coverage | ||
| ADMA BIOLOGICS | 16,370 | +2,63 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 42,540 | +1,17 % | Mineralys Therapeutic: Aktie gibt nach umfangreichen Insiderverkäufen nach |
MARVEL BIOSCIENCES CORP gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MARVEL BIOSCIENCES CORP finden Sie auf Wallstreet Online.